Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 436

Sort by

Sort Order Select

Journal Articles

ILF2 Antisense Oligonucleotide Therapy and a CRISPR/Cas9-Based Screening for DNA Repair Effectors Identify Synthetic Lethal Approaches Enhancing Myeloma Cells Sensitivity to DNA Damage

Natthakan Thongon, PhD, Christopher Jackson, BS, Pamela Lockyer, MS, Jintan Liu, Andrea Santoni, PhD, Ashley Rose, BS, Guillermo Garcia-Manero, MD, Simona Colla, PhD

Blood (2019) 134 (Supplement_1): 685.

https://doi.org/10.1182/blood-2019-129286

Published: 2019

Journal Articles

Targeting CXCR4, VLA4, and CXCR2 for Hematopoietic Stem Cell Mobilization

Daniel Cancilla, BS, Haresh Thakellapalli, Marvin J Meyers, PhD, Michael P. Rettig, PhD, Ezhilarasi Chendamarai, PhD, Stephanie Christ, MS, Darja Karpova, PhD, Peter G Ruminski, BS, Julie K. Ritchey, Dwight M. Morrow, PhD, Michael Prinsen, John F. DiPersio, MD PhD

Blood (2019) 134 (Supplement_1): 1916.

https://doi.org/10.1182/blood-2019-124373

Published: 2019

Journal Articles

Engineering CpG Deoxynucleotide-Conjugated Gold Nanoparticles for Enhanced Anti-Lymphoma Effects in an Immune Competent Lymphoma Model

Adam Yuh Lin, MD PhD, Jonathan Rink, PhD, Reem Karmali, MD, Colby Shad Thaxton, MD PhD, Leo I. Gordon, MD

Blood (2019) 134 (Supplement_1): 1577.

https://doi.org/10.1182/blood-2019-125308

Published: 2019

Journal Articles

Beyond PD-1: Investigating the Therapeutic Potential of TIGIT Blockade in DLBCL

Nicole Sunseri, MD PhD, Xiufen Chen, PhD, Noemie Wald, PhD, Julie Preillon, PhD, Sonali M. Smith, MD, Gregory Driessens, PhD, Justin Kline, MD

Blood (2019) 134 (Supplement_1): 391.

https://doi.org/10.1182/blood-2019-131493

Published: 2019

Journal Articles

Mechanisms of Iron Clearance from the Joint in FVIII-Deficient Mice after Induced Hemarthrosis

Esther J Cooke, PhD, Chanond A Nasamran, Kathleen M Fisch, Annette von Drygalski, MD PharmD

Blood (2019) 134 (Supplement_1): 157.

https://doi.org/10.1182/blood-2019-131576

Published: 2019

Journal Articles

Development of Novel Second Generation DC/Tumor Fusion Vaccine in Lymphoma

Shira Orr, PhD, Marzia Capelletti, PhD MBBS, Haider Ghiasuddin, Dina Stroopinsky, PhD, Jessica Liegel, MD, Myrna Nahas, MD, Matthew Weinstock, MD, Adam Morin, Robin M. Joyce, MD, Salvia Jain, MD, Jon E. Arnason, MD, Maryam Rahimian, MD, Lina Bisharat, Shufen Meng, MD, Donald Kufe, MD, Jacalyn Rosenblatt, MD, David E. Avigan, MD

Blood (2019) 134 (Supplement_1): 392.

https://doi.org/10.1182/blood-2019-124768

Published: 2019

Journal Articles

Allogeneic Chimeric Antigen Receptor-Invariant Natural Killer T Cells Exert Both Direct and Indirect Antitumor Effects through Host CD8 T Cell Cross-Priming

Federico Simonetta, MD PhD, Toshihito Hirai, MD PhD, Juliane K. Lohmeyer, MD, Kristina Maas-Bauer, MD, Maite Alvarez, PhD, Arielle S. Wenokur, Jeanette Baker, Amin Aalipour, PhD, Samuel Haile, PhD, Crystal L. Mackall, MD, Robert S. Negrin, MD

Blood (2019) 134 (Supplement_1): 867.

https://doi.org/10.1182/blood-2019-122515

Published: 2019

Journal Articles

TNB-486, a Novel Fully Human Bispecific CD19 x CD3 Antibody That Kills CD19-Positive Tumor Cells with Minimal Cytokine Secretion

Harbani Malik, PhD, Ben Buelow, MD PhD, Udaya Rangaswamy, PhD, Aarti Balasubramani, Andrew Boudreau, Kevin Dang, Laura Davison, PhD, Shelley Force Aldred, Katherine Marie Harris, MD, Suhasini Iyer, PhD, Brett Jorgensen, PhD, Duy Pham, MBA, Kirthana Prabhakar, Ute Schellenberger, PhD, Harshad Ugamraj, Nathan Trinklein, PhD, Wim Van Schooten, PhD

Blood (2019) 134 (Supplement_1): 4070.

https://doi.org/10.1182/blood-2019-123226

Published: 2019

Journal Articles

Microrna-191 Regulates T-Cell Clonal Expansion during Graft-Versus-Host Disease

Chuanfeng Xiong, MD, Wei Huang, MD PhD, Xiaoli Nie, MD PhD, Ying Huang, MD PhD, Yiqun Jiao, MD, Yujing Zou, PhD, Charles Huang, Emilio Feijoo, Dong Pan, PhD, Diana M Cardona, MD, Nelson J. Chao, MD, Qi-jing Li, PhD, Benny J. Chen, MD

Blood (2019) 134 (Supplement_1): 4433.

https://doi.org/10.1182/blood-2019-130179

Published: 2019

Journal Articles

Neddylation Pathway Regulates Treg Differentiation and T Cell Function in Chronic Lymphocytic Leukemia (CLL) Ex Vivo and Murine In Vivo Studies

Scott R Best, BS, Vi Lam, Nur Bruss, BS, Taylor Hashiguchi Rowland, BS, Adam S. Kittai, MD, Tingting Liu, Allison J Berger, PhD, Alexey Danilov, MD PhD

Blood (2019) 134 (Supplement_1): 4313.

https://doi.org/10.1182/blood-2019-123600

Published: 2019

Journal Articles

Artesunate Inhibits Graft-Versus-Host Disease in Mice Via a Mechanism of Inducing Mitochondrial Calcium Overloading in Activated T Cells

Ying Wang, PhD, Shan He, PhD, Yongnian Liu, Robert Hooper, PhD, Hongshuang Yu, Yuanyuan Tian, Bui Tien, Bryant M Schultz, John W Elrod, PhD, Jonathan Soboloff, Yi Zhang, MD PhD

Blood (2019) 134 (Supplement_1): 4432.

https://doi.org/10.1182/blood-2019-131115

Published: 2019

Journal Articles

Myeloid-Derived Suppressor Cells As Potential Contributors to Pregnancy-Associated Lymphoma Progression

Netanel A Horowitz, MD, Noam Bettman, PhD, Ali Abd El Wahed, Tamar Katz, PhD

Blood (2019) 134 (Supplement_1): 3979.

https://doi.org/10.1182/blood-2019-124292

Published: 2019

Journal Articles

Meds433, a New Dihydroorotate Dehydrogenase Inhibitor, Induces Apoptosis and Differentiation in Acute Myeloid Leukemia

Valentina Gaidano, MD, Paola Circosta, PhD, Alessandro Cignetti, MD PhD, Mohammad Houshmand, Nicoletta Vitale, PhD, Stefano Sainas, PhD, Agnese Pippione, PhD, Manuela Marraudino, PhD, Brigitta Bonaldo, MD, Marta Giorgis, PhD, Donatella Boschi, PhD, Marco Lucio Lolli, PhD, Giuseppe Saglio, MD

Blood (2019) 134 (Supplement_1): 3942.

https://doi.org/10.1182/blood-2019-128085

Published: 2019

Journal Articles

Combination Therapy of Allogeneic HSCT and In Vivo Activated iNKT Cells Prevents Acute Gvhd While Augmenting GVL Effect

Samuel Zeng, Qingxiao Song, MD PhD, Shanshan Tang, Xi Wang, PhD, Yuchen Wang, PhD, Defu Zeng, MD PhD, Lili Yang, PhD

Blood (2019) 134 (Supplement_1): 4439.

https://doi.org/10.1182/blood-2019-130826

Published: 2019

Journal Articles

Influence of Cyclophosphamide on L-Asparaginase-Induced Allergy in Animal Model

Ai Nogami-Hara, PhD, Akira Shimada, MD PhD, Mitsunobu Mio, PhD

Blood (2019) 134 (Supplement_1): 5119.

https://doi.org/10.1182/blood-2019-127179

Published: 2019

Journal Articles

AVM0703, a New Treatment Option for Lymphoma Patients

Theresa Deisher, PhD, Margaret Taylor, Arya Ashok, PhD, Peter Jarzyna, PhD, Yumna Zahid, Stephanie Lee-Diaz, Colleen Rylatt, Kendra Poulin, Vaishnavi Parthasarathy

Blood (2019) 134 (Supplement_1): 5308.

https://doi.org/10.1182/blood-2019-128812

Published: 2019

Journal Articles

Potential Role of IL-39 in the Development of Gvhd

David Bastian, Hung Nguyen, PhD, Yongxia Wu, PhD MD, Steven Douglas Schutt, BS, Mohammed Hanief Sofi, PhD MS, Yuejun Liu, PhD, Eric Bartee, PhD, Xue-Zhong Yu, MD MS

Blood (2019) 134 (Supplement_1): 3206.

https://doi.org/10.1182/blood-2019-131251

Published: 2019

Journal Articles

Reprogramming Leukemia Cells into Antigen Presenting Cells As a Novel Cancer Vaccination Immunotherapy

Miles Hamilton Linde, BS, BA, Christopher G Dove, Sarah F Gurev, Paul Phan, Feifei Zhao, MD, Lindsay P Miller, Ravindra Majeti, MD PhD

Blood (2019) 134 (Supplement_1): 3217.

https://doi.org/10.1182/blood-2019-128577

Published: 2019

Journal Articles

Infusion of Mesenchymal Stem Cells Combined with Epithelial Progenitor Cells Promotes Injured Intestinal Repairing after Hematopoietic Cell Transplantation

Shengyun Zhu, Huiqi Li, Chaoran Lyu, Jing Liang, Lingyu Zeng, MD,PhD, Kailin Xu, MD

Blood (2019) 134 (Supplement_1): 5604.

https://doi.org/10.1182/blood-2019-127584

Published: 2019

Journal Articles

Ruxolitinib, a JAK1/JAK2 Selective Inhibitor, Ameliorates Gastrointestinal and Cutaneous Pathogenesis in MHC-Mismatched Preclinical Models of Acute and Chronic Graft-Versus-Host Disease

Eduardo Huarte, PhD, Melissa Parker, Ashish Juvekar, Julian Oliver, Wenqing Yao, Paul Smith

Blood (2019) 134 (Supplement_1): 5608.

https://doi.org/10.1182/blood-2019-126749

Published: 2019

NARROW

ILF2 Antisense Oligonucleotide Therapy and a CRISPR/Cas9-Based Screening for DNA Repair Effectors Identify Synthetic Lethal Approaches Enhancing Myeloma Cells Sensitivity to DNA Damage

Targeting CXCR4, VLA4, and CXCR2 for Hematopoietic Stem Cell Mobilization

Engineering CpG Deoxynucleotide-Conjugated Gold Nanoparticles for Enhanced Anti-Lymphoma Effects in an Immune Competent Lymphoma Model

Beyond PD-1: Investigating the Therapeutic Potential of TIGIT Blockade in DLBCL

Mechanisms of Iron Clearance from the Joint in FVIII-Deficient Mice after Induced Hemarthrosis

Development of Novel Second Generation DC/Tumor Fusion Vaccine in Lymphoma

Allogeneic Chimeric Antigen Receptor-Invariant Natural Killer T Cells Exert Both Direct and Indirect Antitumor Effects through Host CD8 T Cell Cross-Priming

TNB-486, a Novel Fully Human Bispecific CD19 x CD3 Antibody That Kills CD19-Positive Tumor Cells with Minimal Cytokine Secretion

Microrna-191 Regulates T-Cell Clonal Expansion during Graft-Versus-Host Disease

Neddylation Pathway Regulates Treg Differentiation and T Cell Function in Chronic Lymphocytic Leukemia (CLL) Ex Vivo and Murine In Vivo Studies

Artesunate Inhibits Graft-Versus-Host Disease in Mice Via a Mechanism of Inducing Mitochondrial Calcium Overloading in Activated T Cells

Myeloid-Derived Suppressor Cells As Potential Contributors to Pregnancy-Associated Lymphoma Progression

Meds433, a New Dihydroorotate Dehydrogenase Inhibitor, Induces Apoptosis and Differentiation in Acute Myeloid Leukemia

Combination Therapy of Allogeneic HSCT and In Vivo Activated iNKT Cells Prevents Acute Gvhd While Augmenting GVL Effect

Influence of Cyclophosphamide on L-Asparaginase-Induced Allergy in Animal Model

AVM0703, a New Treatment Option for Lymphoma Patients

Potential Role of IL-39 in the Development of Gvhd

Reprogramming Leukemia Cells into Antigen Presenting Cells As a Novel Cancer Vaccination Immunotherapy

Infusion of Mesenchymal Stem Cells Combined with Epithelial Progenitor Cells Promotes Injured Intestinal Repairing after Hematopoietic Cell Transplantation

Ruxolitinib, a JAK1/JAK2 Selective Inhibitor, Ameliorates Gastrointestinal and Cutaneous Pathogenesis in MHC-Mismatched Preclinical Models of Acute and Chronic Graft-Versus-Host Disease

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only